Clinical Trial Update: Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema. The trial is completed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• PHA-022121

Snippet

Sponsor: Pharvaris Netherlands B.V. | Conditions: Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Status: COMPLETED | Results posted: 2025-12-17